{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T17:08:55Z","timestamp":1773680935939,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Disease-modifying therapies with amyloid-antibodies will soon be available for patients with early Alzheimer\u2019s disease, which necessitates diagnostic and therapeutic resources in hospital and outpatient settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Austrian Alzheimer Society developed an online questionnaire to survey Austrian hospital-based departments of neurology and psychiatry regarding resources for amyloid-antibody therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between May and October 2023, 30\u00a0out of 41\u00a0neurology (73%) and 12\u00a0out of 33\u00a0psychiatry departments (36%) responded. The number of first examinations per year and center ranges between\u00a00 in centers accepting only secondary referrals and 500, median 100.<\/jats:p>\n                    <jats:p>Of the patients 30% (median; range 0\u201380%) achieve a\u00a0mini-mental state examination sum score \u2265\u202f22 constituting an early disease stage. First visits comprise medical history, clinical examination, routine blood sampling and neurocognitive screening in 90\u2013100% of patients, magnetic resonance imaging in\u00a090% (median; range 10\u2013100%), amyloid-PET in 5% (0\u201370%), cerebrospinal fluid analysis (A\u00df42, A\u00df40, tau, phospho-tau) in 25% (0\u201390%) and Apo\u2011E testing in 2.5% (0\u2013100%). To assess the amyloid status 18\u00a0centers (44%) prefer amyloid-PET to lumbar puncture, 20 (49%) vice versa and 15 centers intend to offer amyloid-antibody therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Differences between centers and federal states were observed regarding hospital-based resources for amyloid-antibody therapies. A\u00a0substantial need exists for early dementia diagnosis, medical, neuropsychological, nursing and administrative resources, adequate space, access to amyloid-PET and MRI. All centers highlighted the need for structured patient pathways and multidisciplinary care networks, including neurologists, psychiatrists, radiologists, neuropsychologists operating in clinical practice, rehabilitation and dementia care settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00508-025-02608-5","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:00:50Z","timestamp":1757070050000},"page":"137-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Resources of Austrian hospital-based departments of neurology and psychiatry for new amyloid-antibody therapies in early Alzheimer dementia"],"prefix":"10.1007","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9982-1420","authenticated-orcid":false,"given":"Gerhard","family":"Ransmayr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Eicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Mraczansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Braoudaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Defrancesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Struhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bancher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dal-Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Marksteiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhold","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"St\u00f6gmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"2608_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck\u00a0CH, Swanson\u00a0CJ, Aisen\u00a0P, et\u00a0al. Lecanemab in Early Alzheimers Disease. N\u00a0Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"2608_CR2","unstructured":"https:\/\/us.eisai.com\/"},{"key":"2608_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims\u00a0JR, Zimmer\u00a0JA, Evans\u00a0CD, et\u00a0al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"2608_CR4","unstructured":"https:\/\/www.ema.europa.eu. Accessed 25 July 2025."},{"key":"2608_CR5","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30","author":"J Cummings","year":"2023","unstructured":"Cummings\u00a0J, Apostolova\u00a0L, Rabinovici\u00a0GD, et\u00a0al. for the Alzheimer\u2019s Disease and Related Disorders Therapeutics Work Group. Lecanemab: Appropr Use Recomm J Prev Alz Dis 2023. 2023; https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"Lecanemab: Appropr Use Recomm J Prev Alz Dis 2023"},{"key":"2608_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1046\/j.1563-258x.2002.01123.x.a","volume":"152","author":"J Wanchata","year":"2002","unstructured":"Wanchata\u00a0J. Die Epidemiologie der Demenzen (The Epidemiology of Dementias). Wien Med Wochenschr. 2002;152:52\u20136. https:\/\/doi.org\/10.1046\/j.1563-258x.2002.01123.x.a.","journal-title":"Wien Med Wochenschr"},{"key":"2608_CR7","doi-asserted-by":"publisher","unstructured":"GBD. Dementia Forecasting Collaborators Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 Lancet Public Health. 2019. https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8, 2022 Feb;7(2):e105\u2013e125.","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"2608_CR8","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson\u00a0PT, Dickson\u00a0DW, Trojanowski\u00a0JQ, et\u00a0al. Limbic-predominant age related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503\u201327. https:\/\/doi.org\/10.1093\/brain\/awz099.","journal-title":"Brain"},{"key":"2608_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-014-1349-0","volume":"128","author":"JF Crary","year":"2014","unstructured":"Crary\u00a0JF, Trojanowski\u00a0JQ, Schneider\u00a0JA, et\u00a0al. Primary age-related tauopathy (PART): a\u00a0common pathology associated with human aging. Acta Neuropathol. 2014;128:755\u201366. https:\/\/doi.org\/10.1007\/s00401-014-1349-0. Epub 2014 Oct 2810.","journal-title":"Acta Neuropathol"},{"key":"2608_CR10","unstructured":"www.who.int\/news-room\/fact-sheets\/detail\/dementia"},{"key":"2608_CR11","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3233\/JAD-200786","volume":"79","author":"J Yuan","year":"2021","unstructured":"Yuan\u00a0J, Maserejian\u00a0N, Liu\u00a0Y, et\u00a0al. Severity Distribution of Alzheimer\u2019s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. J\u00a0Alzheimers Dis. 2021;79:807\u201317. https:\/\/doi.org\/10.3233\/JAD-200786.","journal-title":"J Alzheimers Dis"},{"key":"2608_CR12","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack\u00a0CR Jr., Andrews\u00a0JS, Thomas\u00a0G, et\u00a0al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 2024;20:5143\u201369. https:\/\/doi.org\/10.1002\/alz.13859.","journal-title":"Alzheimers Dement"},{"key":"2608_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00508-024-02465-8","volume":"137","author":"S Lee","year":"2025","unstructured":"Lee\u00a0S, St\u00f6gmann\u00a0E. Monoclonal anti-amyloid antibody treatment: the epidemiological profile of the targetpatients in Austria and the status of treatment-eligible patients registered at an outpatient memory clinic. Wien Klin Wochenschr. 2025;137:189\u201392. https:\/\/doi.org\/10.1007\/s00508-024-02465-8. Epub 2024 Oct 23..","journal-title":"Wien Klin Wochenschr"},{"key":"2608_CR14","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.000000000020777","volume":"101","author":"RR Pittock","year":"2023","unstructured":"Pittock\u00a0RR, Aakre\u00a0JA, Castillo\u00a0AM, et\u00a0al. Eligibility for Anti-Amyloid Treatment in a\u00a0Population-Based Study of Cognitive Aging. Neurology. 2023;101:e1837\u2013e49. https:\/\/doi.org\/10.1212\/WNL.000000000020777.","journal-title":"Neurology"},{"key":"2608_CR15","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00415-025-13059-3","volume":"272","author":"B Mittler","year":"2025","unstructured":"Mittler\u00a0B, Cambi\u00a0X, Biskach\u00a0M, et\u00a0al. Patient journey and decision processes for anti-amyloid therapy in Alzheimer\u2019s disease. J\u00a0Neurol. 2025;272:341. https:\/\/doi.org\/10.1007\/s00415-025-13059-3.","journal-title":"J Neurol"},{"issue":"e160","key":"2608_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bjo.2024.747","volume":"10","author":"M Defrancesco","year":"2024","unstructured":"Defrancesco\u00a0M, Gizewski\u00a0ER, Mangesius\u00a0S, et\u00a0al. Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer\u2019s disease: real-world data from an Austrian psychiatric memory clinic population. BJPsych open. 2024;10(e160):1\u20139. https:\/\/doi.org\/10.1192\/bjo.2024.747.","journal-title":"BJPsych open"},{"issue":"8","key":"2608_CR17","doi-asserted-by":"publisher","first-page":"afac173","DOI":"10.1093\/ageing\/afac173","volume":"51","author":"W Bai","year":"2022","unstructured":"Bai\u00a0W, Chen\u00a0P, Cai\u00a0H, et\u00a0al. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50\u00a0years and older: a\u00a0meta-analysis and systematic review of epidemiology studies. Age Ageing. 2022;51(8):afac173. https:\/\/doi.org\/10.1093\/ageing\/afac173.","journal-title":"Age Ageing"},{"key":"2608_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3233\/JAD-2010-1263","volume":"19","author":"MA Lovell","year":"2010","unstructured":"Lovell\u00a0MA. Similarities and differences between mild cognitive impairment and Alzheimer\u2019s disease. J\u00a0Alzheimers Dis. 2010;19:219. https:\/\/doi.org\/10.3233\/JAD-2010-1263.","journal-title":"J Alzheimers Dis"},{"key":"2608_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.16000447.2008.01326.x","volume":"119","author":"AJ Mitchell","year":"2009","unstructured":"Mitchell\u00a0AJ, Shiri-Feshki\u00a0M. Rate of progression of mild cognitive impairment to dementia\u2014meta-analysis of41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119:252\u201365. https:\/\/doi.org\/10.1111\/j.16000447.2008.01326.x. Epub 2008 Feb 1.","journal-title":"Acta Psychiatr Scand"},{"key":"2608_CR20","unstructured":"www.statistik.at"},{"key":"2608_CR21","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1212\/WNL.0000000000010022","volume":"95","author":"FJ Wolters","year":"2020","unstructured":"Wolters\u00a0FJ, Chibnik\u00a0LB, Waziry\u00a0R, et\u00a0al. Twenty-seven-year time trends in dementia incidence in Europe and the United States. Alzheimer Cohorts Consortium Neurol. 2020;95:e519\u2013e31. https:\/\/doi.org\/10.1212\/WNL.0000000000010022.","journal-title":"Alzheimer Cohorts Consortium Neurol"},{"key":"2608_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/emj.19.5.432","volume":"19","author":"S Teece","year":"2002","unstructured":"Teece\u00a0S, Crawford\u00a0I. Bed rest after lumbar puncture. Emerg Med\u00a0J. 2002;19:432\u20133.","journal-title":"Emerg Med J"},{"key":"2608_CR23","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-1263","author":"EE Smith","year":"2010","unstructured":"Smith\u00a0EE, Phillips\u00a0NA, Feldman\u00a0H, et\u00a0al. Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future. Res Alzheimers Dis. 2010; https:\/\/doi.org\/10.3233\/JAD-2010-1263. 219.","journal-title":"Res Alzheimers Dis"},{"key":"2608_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/13872877241289788","volume":"102","author":"D Shir","year":"2024","unstructured":"Shir\u00a0D, Shiner\u00a0T, Bregman\u00a0N. Anti-amyloid treatments for Alzheimer\u2019s disease: A\u00a0study on physicians\u2019perspectives. J\u00a0Alzheimers Dis. 2024;102:627\u201332. https:\/\/doi.org\/10.1177\/13872877241289788.","journal-title":"J Alzheimers Dis"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02608-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02608-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:30:13Z","timestamp":1773678613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02608-5"}},"subtitle":["A survey of the Austrian Alzheimer Society"],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":24,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2608"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02608-5","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.\u00a0Ransmayr, E.\u00a0Eicher, J.\u00a0Mraczansky, E.\u00a0Braoudaki, M.\u00a0Defrancesco, W.\u00a0Struhal, C.\u00a0Bancher, P.\u00a0Dal-Bianco, J.\u00a0Marksteiner, R.\u00a0Schmidt and E.\u00a0St\u00f6gmann are members of the managing board of the Austrian Alzheimer Society (\u00d6AG) and received travel and accommodation expense support from the \u00d6AG. G.\u00a0Ransmayr received honoraria for consultations from AbbVie GmbH, Eisai GmbH, Roche Austria GmbH. E.\u00a0Braoudaki received an honorarium from the Austria Alzheimer Society for designing, programming and maintaining the survey. E.\u00a0Eicher: no declarations and disclosures. J.\u00a0Mraczansky: no declarations and disclosures. M.\u00a0Defrancesco: no further declarations and disclosures. W.\u00a0Struhal received third party funds from the K.\u00a0Landsteiner Privatuniversit\u00e4t f\u00fcr Gesundheitswissenschaften, \u00d6sterreichische Alzheimer Gesellschaft, Donau-Universit\u00e4t Krems, \u00d6GN, Manz-Rechtsverlag and royalties from Springer, Elsevier, Oxford University Press, Manz. C.\u00a0Bancher received speakers and consultation honoraria as well as congress support from Schwabe Austria GmbH, Eisai GmbH, Eli Lilly GmbH, Novartis Pharma GmbH, Roche-Austria GmbH P.\u00a0Dal-Bianco: no further declarations and disclosures. J.\u00a0Marksteiner: no further declarations and disclosures, R.\u00a0Schmidt: no further declarations and disclosures. E.\u00a0St\u00f6gmann\u2019s institution (Medical University of Vienna, Austria) received financial support by research grants for research in AD: Eisai, EU Horizon 2020, Austrian Research Promotion Agency. Elisabeth St\u00f6gmann\u2019s institution (Medical University of Vienna, Austria) received financial support for participation in clinical trials from Biogen, Novo Nordisc and Roche Diagnostics. E.\u00a0St\u00f6gmann received honoraria (consultations, lectures, speaker bureaus, educational events, advisory boards) from pharmaceutical companies: Biogen, Roche, Novo Nordisc, Eisai, Novartis, Sanofi and Eli Lilly. E.\u00a0St\u00f6gmann held leadership in scientific societies: Austrian Alzheimer Association.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All authors gave their informed consent to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}